Skip to content
Psychiatrist.com Logo
  • JCP
  • PCC
  • News
  • CME
  • About
  • Authors & Reviewers
  • Sign In
  • Subscribe
Advanced Search

Menu

  • JCP
  • PCC
  • News
  • CME
  • About
  • Authors & Reviewers
  • Sign In
  • Subscribe
Sign in Subscribe

Clinical Topics

View All
  • Addiction
  • ADHD
  • Alzheimer’s Disease
  • Anxiety
  • Bipolar Disorder
  • Depression
  • Movement Disorders
  • Neurology
  • OCD
  • Psychopharmacology
  • PTSD and Trauma
  • Schizophrenia/Schizoaffective Disorders
  • Sleep
  • Tardive Dyskinesia
  • View All

Collections

View All
  • Academic Highlights
  • Auvelity: Information from Industry
  • Banner Alzheimer’s Institute
  • Clinical & Practical Psychopharmacology
  • Early Career Psychiatrists
  • Focus on Childhood and Adolescent Mental Health
  • Focus on Geriatric Psychiatry
  • Focus on Psychotherapy
  • Focus on Suicide
  • Focus on Psychosis
  • Focus on Women’s Mental Health
  • Rounds in the General Hospital
  • UZEDY: Information from Industry
  • View All
Back to top Open menu arrow
Download PDF Reprints
No sections available

The Journal of
Clinical Psychiatry

Free access
Addiction

Letter to the Editor January 15, 1998

Naltrexone-Induced Reduction of Tobacco Intake

Arturo G. Lerner; Igor Oyffe; Mircea Sigal

J Clin Psychiatry 1998;59(1):30-31

Article Abstract

Letter to the Editor

Naltrexone-Induced Reduction of Tobacco Intake

 

About the Authors

  • Arturo G. Lerner
    View full profile
  • Igor Oyffe
    View full profile
  • Mircea Sigal
    View full profile
Download Free PDF

This PDF is free for all visitors!

Related News Articles

Cannabis Use Climbs in People With Psychosis The Intelligence Effect on Alcohol Addiction Weekly Mind Reader: What Can’t GLP-1s Do?

Sponsored

PsychCase360: Choosing the Right Long-Acting Injectable for Patients With Schizophrenia
Explore two real-world schizophrenia cases with Roueen Rafeyan, MD and Melissa Vitale, PMHNP as they discuss challenges with medication adherence, transitioning to long-acting injectables (LAIs), and personalizing treatment strategies to improve patient outcomes.

Related JCP Articles

Nonmedical Use and Substance Use Disorder Symptoms in US Adults Co-Prescribed Opioids and Benzodiazepines N-acetylcysteine for Co-occurring PTSD and Alcohol Use Disorder: A Double-Blind, Randomized Controlled Trial Effects of Alcohol Use on Cognition in Individuals With Neurocognitive Disorders

Related PCC Articles

Dexamethasone and Cyproheptadine Misuse Amnesia Associated With Recreational Cannabis Use in an Adolescent Reversible Cerebral Vasoconstriction Syndrome and Marijuana
Cover of The Journal of Clinical Psychiatry, September 2025 issue, featuring article titles on postpartum distress, aripiprazole monohydrate injectables for schizophrenia and bipolar disorder, and other psychiatric topics.

Vol 86 • 2025 • Number 3

Read the Current Issue

Original Research

Treatment Use and Preference in a Diverse Sample of Women With Mood Disorders

Original Research

Klotho and Matrix Metalloproteinase-9 Levels and Their Association with Inhibitory Dyscontrol in Adolescents with First-Episode Major Affective Disorders

Original Research

Niacin-Induced Response in Early Psychosis

Original Research

Early Ketamine Response Reduces Suicidal Events at 3 Months

Letter to the Editor

Suicide Risk among Patients with Bipolar Disorder: Sleep Disruption versus Benzodiazepine Use

Original Research

Effect of Nature Videos on the Burden of Caregivers of Patients with Dementia

View current Issue

Related Articles

JCP
Detecting Misuse of Prescription Opioids
Letter to the Editor

Detecting Misuse of Prescription Opioids

October 21, 2024

The authors discuss the difficulty in screening for opioid misuse and the need for clinicians to gain confidence in initiating difficult discussions with patients on long-term opioid treatment.
Vania Modesto-Lowe, Alyssa Crispino, Michael Salley
PCC
Harm Reduction in Adolescent Inhalant Use
Letter to the Editor

Harm Reduction in Adolescent Inhalant Use

October 15, 2024

The authors discuss harm reduction efforts targeting inhalant use in the adolescent population.
Vania Modesto-Lowe, Roseane Rodrigues, Deanna Sgambato
PCC
Zeroing in on Xylazine
Letter to the Editor

Zeroing in on Xylazine

August 15, 2024

Dr Kaur and colleagues discuss the need to raise awareness among US public and health care professionals about xylazine due to its infiltration into the illicit drug supply.
Jasleen Kaur, Megan Nosol, Vania Modesto-Lowe

Watch the New PsychCase360

Explore two real-world schizophrenia cases
Promotional banner for a video titled “Choosing the Right LAI for Patients With Schizophrenia” featuring headshots of Roueen Rafeyan, MD, and Melissa Vitale, PMHNP, with a “Watch Now” button.

Subscribe to read
more articles

Subscribe
The Journal of Clinical Psychiatry
The Primary Care Companion for CNS Disorders

ELSEWHERE:

  • ABOUT
  • ADVERTISERS
  • MEDIA RELATIONS
  • REPRINTS & PERMISSIONS
  • CONTACT US
  • CUSTOMER SUPPORT

FOLLOW US:

  • X
  • FACEBOOK
  • INSTAGRAM
  • LINKEDIN
  • SIGN IN

  • JOIN THE EMAIL LIST


SUBSCRIBE NOW
An image of the Psychiatrist.com logo mark
  • Privacy Policy
  • Terms of Use
  • Physicians Postgraduate Press, Inc.
  • JCP ISSN: Online 1555-2101, Print 0160-6689
  • PCC ISSN: Online 2155-7780, Print 2155-7772
  • MedFair.com US Patent No. 684794
  • © Copyright 2025 | Physicians Postgraduate Press, Inc. | LifeLong Learning For Clinicians
  • Sitemap